Biothera to Present Cancer Immunotherapy Research at BIO International Convention.EAGAN, Minn. -- Biothera, a biotechnology company developing pharmaceuticals that prime the innate immune system
Steven J. Karel, Biothera's chief of technology operations, will discuss the company's novel technology and its applications in the areas of oncology, anti-infectives and hematopoiesis Hematopoiesis The process by which the cellular elements of the blood are formed. The three main types of cells are the red cells (erythrocytes), which serve to carry oxygen, the white cells (leukocytes), which function in the prevention of and recovery from . "Our technology has the potential to dramatically enhance both existing and developmental drug treatments for most major types of cancer," said Daniel K. Conners, Biothera founder and chairman. "Our lead compound, Imprime PGG PGG Purple, Green, and Gold (Mardi Gras beads colors) PGG Project Galactic Guide PGG Patrol Gunboat (Missile) PGG Pendleton Grain Growers, Inc. (Pendleton, OR, USA) [TM], is a biological response modifier biological response modifier n. A substance, such as interferon, that is produced naturally or manufactured as a drug designed to strengthen, direct, or restore the body's immune response against infection or cancer. that enhances specific innate immune cell responses." Biothera has two active Investigational New Drug (IND) filings with the U.S. Food and Drug Administration. The company has completed: * Two Phase I clinical trials with in support of its cancer IND for the use of Imprime PGG in combination with anti-cancer monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). . * A Phase I/II trial with Imprime PGG in combination with a hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. growth factor. Biothera plans to initiate multiple Phase Ib and Phase II studies with Imprime PGG in combination with anti-cancer monoclonal antibodies.
Event Details
Meeting: Biotechnology Industry Organization (BIO)
International Convention
Presenter: Steven J. Karel
Biothera Chief of Technology Operations
Date/Time: Tuesday, May 8th at 2:15 pm
Location: Boston Convention & Exhibition Center
BIO Business Forum
Level 1 of BCEC at the North Lobby
Biothera will conduct individual meetings with corporate partner and licensing candidates during the convention. To schedule a meeting, contact Robert J. Brown, senior vice president, Corporate Development, at 651-675-0300 or at rbrown@biotherapharma.com. About Biothera, the Immune Health Company Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals that engage the innate immune system to fight cancer. Other applications include hematopoietic (white blood cell) recovery and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. . Website: www.biotherapharma.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion